Immuron (IMRN) Stock: Buy, Sell, or Hold?
IMRN - Immuron Limited American Depositary Shares
$1.09
-0.04 (-3.54%)
âŧ
5d:
-6.03%
30d:
-6.84%
90d:
-2.68%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 27, 2026
0d
Get Alerted When IMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IMRN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IMRN is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: IMRN is currently trading at $1.09, which is considered slightly low relative to its 30-day fair value range of $1.05 to $1.48.
Technical Outlook: Technically, IMRN is showing sideways momentum. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: IMRN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.88 (+255.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMRN is showing sideways momentum. The price is currently testing key support at $1.08. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: IMRN scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.88 (+255.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.05 -
$1.48
Company Quality Score
40/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 255.9% below Wall St target ($3.88)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.05 -
$1.48
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.08
Resistance Level
$1.30
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-72.19
Wall Street Target
$3.88
(+255.9%)
Revenue Growth (YoY)
7.2%
Profit Margin
-47.7%
Share & Embed Analysis
Last updated: October 03, 2026 9:59 AM ET
Data refreshes hourly during market hours. Next update: 10:59 AM
Data refreshes hourly during market hours. Next update: 10:59 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 52 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 46 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
